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SUMMARY 
Background: The role and dose of anticoagulants in thrombosis prophylaxis for 
cancer patients with central venous catheters (CVCs) is controversial. 
Methods: 1590 cancer patients receiving chemotherapy via CVCs were randomised 
to no warfarin [control] vs warfarin [either daily fixed dose 1mg warfarin (FDW) or 
daily dose adjusted warfarin (DAW) to maintain International Normalised Ratio 
between 1.5 and 2.0].  Clinicians ‘certain’ of the benefit of warfarin randomised 
between FDW and DAW.  The primary outcome measure is the incidence of 
radiologically proven, symptomatic catheter-related thrombosis (CRT); secondary 
outcome measures include toxicity, incidence of all thromboses and overall survival.  
Findings: Compared to control, warfarin (79% FDW; 21% DAW) reduced neither 
CRT [5.9% vs 5.9%; relative risk (RR) 0.99, (95% Confidence Interval (CI) 0.57-
1.72), p=0.98] nor all thrombotic events [7.4% vs 9.4%; RR 0.78 (95%CI 0.50-1.24), 
p=0.30].  However, compared to FDW only, DAW was superior in preventing CRT 
[2.8% vs 7.2%; RR 0.38, (95%CI 0.20-0.71), p=0.002] but not all thromboses [5.5% 
vs 7.9%; RR 0.70 (95%CI 0.43-1.14), p=0.15].  Major bleeding events were rare; an 
excess was observed with warfarin compared to control (7 vs 1, p=0.07) and with 
DAW compared to FDW (16 vs 7, p=0.09).   A combined endpoint of thromboses 
and major bleeding showed no difference between warfarin and control or between 
DAW and FDW. No survival difference was demonstrated in either comparison.  
Interpretation: Thrombosis rates were low (5.3%); there is no benefit in using 
warfarin in comparison to no warfarin for the prophylaxis of symptomatic CRT or 
other thromboses in cancer patients.   
    Summary: 250 words 
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INTRODUCTION 
Venous thromboembolism (VTE) is a well documented complication of cancer and 
may be linked to tumoral production of a range of procoagulant factors, certain 
chemo and hormone therapies and the use of central venous catheters (CVCs).   
Evidence of VTE is found at post mortem in around 50% of cancer patients1, but 
remains an under-diagnosed and under-treated condition in life.  The last decade 
has seen an enormous increase in the use of CVCs to deliver infusional 
chemotherapy and, with this, recognition of catheter-related thrombosis (CRT) as a 
source of considerable morbidity2.   
Hitherto, trials of thromboprophylaxis for adult cancer patients undergoing 
chemotherapy with CVCs have not produced a clear consensus on the role of 
anticoagulation. Differing definitions of CRT and inconsistent assessment of VTE 
have made comparisons problematic. 
Two early influential studies in the 1990s addressed the potential of anticoagulants 
to reduce the incidence of thrombotic events3,4 and although small, suggested a 
benefit in using prophylactic anticoagulation, reducing thrombosis rates with minimal 
toxicity.  However, trials since the turn of the century have challenged this thinking 
and have revealed no advantage of anticoagulant intervention in the reduction of 
thrombosis rates for patients having chemotherapy via CVCs5,6,7,8. 
A survey of clinical opinion of thromboprophylaxis in patients receiving infusional 
chemotherapy via a CVC was undertaken in 1999 and informed the design of this 
study. Completed by over 200 UK cancer clinicians, the results indicated that 60% of 
clinicians used warfarin routinely as a thromboprophylactic (95% of these clinicians 
prescribed 1mg warfarin daily) and 20% of clinicians were certain of the indication 
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for warfarin intervention and hence would not be willing to randomise to a 
comparison with a ‘no warfarin’ arm.   
This paper reports the outcome of a large open label, multicentre trial, investigating 
the utility of warfarin in thromboprophylaxis, in cancer patients with CVCs. 
 
Patients and Methods 
Sixty-eight UK clinical centres with nursing teams dedicated to catheter care 
participated in the trial.  The centres received ethical approval from West Midlands 
Multi-Centre Research Ethics Committee and all patients consented in writing. 
Patient Eligibility 
Patient eligibility covered the following inclusion criteria:  histologically confirmed 
diagnosis of cancer; requirement for CVC insertion for administration of 
chemotherapy; aged at least 16 years and with adequate hepatic, renal and 
haematological function.  Exclusion criteria comprised: patients with a 
contraindication to warfarin; patients taking warfarin and pregnant or lactating 
women. 
Trial Design 
The study was structured to encompass contemporary clinical opinion noted from 
the pre-trial survey. Clinicians who were ‘uncertain’ of the benefits of warfarin in 
thromboprophylaxis, randomised patients to no warfarin (control) vs daily 1mg fixed 
dose warfarin (FDW) vs daily dose adjusted warfarin (DAW) to maintain the 
international normalised ratio (INR) between 1.5 and 2.0.   Clinicians who were 
‘certain’ of the indication for warfarin, randomised patients between FDW and DAW.   
All preferences were those of clinicians.  Initially, the ‘uncertain indication’ 
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preference had 3 arms, as previously described; however, investigators 
subsequently requested that a 2 arm option of control vs FDW be included (Figure 
1).  The trial design was amended accordingly by the Steering Committee after 141 
patients had been randomised in the 3 arm comparison and 245 to the ‘certain’ 
preference.  Randomisation was executed via a computerised block algorithm and 
accessed by telephone and fax. Stratification was based on three thrombosis risk 
factors; sclerosant potential of the cytotoxic regimen (low or high); site of placement 
of the catheter (peripheral or central); and duration of drug infusion (less than, or 
greater and equal to 24 hours; for duration of one chemotherapy cycle intravenous 
infusion).   
This trial design enabled two key hypotheses to be tested: (i) whether warfarin 
reduces CRT relative to control (‘warfarin evaluation’ comparison) and (ii) whether 
DAW is superior to FDW (‘dose evaluation’ comparison). 
Treatment Plan 
All types of CVCs were permitted in the study; the correct position of the catheter tip 
(at the junction of the superior vena cava and the right atrium) was checked by chest 
X-ray post CVC insertion.  Randomisation and start of warfarin, if allocated, was 
permitted from 3 days prior to CVC insertion (to enable sufficient exposure to 
warfarin for the immediate post insertion period).  Warfarin was taken daily until 
thrombosis or catheter removal for any reason and could be temporarily 
discontinued in the face of thrombocytopenia (platelets50x109/L).  Agreed protocols 
for INR monitoring on all treatment arms were provided and treatment of VTE was 
carried out according to local practice.  
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Outcome Measures 
The primary outcome measure reported is the incidence of radiologically confirmed 
symptomatic catheter-related thrombotic events, i.e. occurring in the venous system 
draining the catheter, or pulmonary emboli (PE) in patients who had catheter 
complications. Secondary outcome measures include non catheter-related 
thrombotic events (occurring in the arterial system, in the venous system not 
draining the catheter and PE in patients with no catheter complications), catheter 
patency, warfarin-related adverse events (bleeding and raised INR), overall survival, 
catheter-related infections and health service related costs (not reported here).  All 
thromboses were radiologically confirmed by venogram, ultrasound or ventilation-
perfusion (VQ) / Spiral CT and classified as CRT or non-CRT by two investigators, 
blinded to treatment allocation, using a central protocol. Thromboses that were 
suspected but not radiologically confirmed were recorded under CVC complications. 
Major bleeding episodes were defined as intracranial, retroperitoneal, requiring 
transfusion or hospitalisation or directly leading to death9.  Increased INR was 
classified by the investigators as: mild (2<INR<5), moderate (5≤INR<8) or severe 
(INR8).    Dates of death were obtained from the case record forms or from the 
Office of National Statistics (ONS) in April 2007.  
 
Statistical methods 
Sample size calculations were made on the following assumptions: the thrombotic 
event rate for patients on no warfarin was around 25% and if warfarin were to reduce 
this rate by 10%, this would be a medically worthwhile improvement.  With 800 
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patients entered into the uncertain indication (400 no warfarin and 400 warfarin), 
there would be >90% power to detect a 10% difference.  With 1000 patients 
randomised between warfarin doses, there would be 80% power to detect a 
difference of 7% in thrombotic event rates between the two dosing schedules. The 
trial had approximately 90% power to detect a 10% difference in long term survival 
comparing warfarin and no warfarin groups.   
 
Rates of thrombotic events were compared using Mantel-Haenszel chi-square tests, 
stratified by randomisation option.  Differences between treatments are expressed 
as relative risk (RR) with 95% confidence intervals (CI). The analysis was carried out 
on an intention-to-treat basis, with a small number of ‘unknown outcome’ patients 
combined with those not experiencing an event.  Sensitivity analysis confirmed the 
validity of the assumption.  CRT events were also analysed as time to event data 
with time to thrombosis censored at date of CVC removal in those with no event.  In 
addition, time to thrombosis in patients with an event was compared using Wilcoxon 
tests.   Duration of catheter patency was calculated as time from catheter insertion to 
thrombotic event or CVC complication and censored at CVC removal for those 
patients with no event.  Overall survival, measured from date of randomisation to 
date of death or date last seen alive, was analysed using Kaplan-Meier10 estimation 
and log-rank tests11.  Major bleeding episodes were compared using Fisher’s Exact 
test. All p-values are two-sided. 
Role of the Funding Source 
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The Medical Research Council and Cancer Research UK funded the salaries of the 
WARP clinical research fellow and data manager respectively; they had no 
involvement in the trial or publication.   
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RESULTS 
WARP recruited 1590 patients between October 1999 and December 2004; 812 
were randomised to the ‘uncertain’ preference (404 to control, 408 to warfarin) and 
778 to the ‘certain’ preference (389 to FDW and 389 to DAW).   The design enabled 
166 (10.4%) patients to contribute to both comparisons.  Due to inclusion of the 
‘uncertain’ indication 2-arm option (control vs FDW), of those patients randomised to 
the warfarin arm of the control comparison, 324 (79.4%) patients received FDW daily 
and 84 (20.6%) received DAW daily (Figure 1).  
 
Patient and CVC characteristics 
Baseline patient and CVC characteristics (Table 1) and are well balanced across the 
study arms.  Peripherally inserted central catheters (PICCs) were used for 58% of 
patients, in keeping with a rising trend in practice. Patients were similar with respect 
to age, treatment length, performance status, disease site and stage of disease 
across all arms.  93% of patients had World Health Organisation (WHO) 
Performance Status of 0 and 1, although 65% had advanced disease; over 50% of 
patients presented with colorectal cancer.  
  Page 10 of 29 
Compliance 
Protocol Compliance 
Of 1590 patients, four were found to be ineligible, three on clinical parameters and 
one declining chemotherapy immediately post randomisation.   Four additional 
patients did not have CVCs inserted post randomisation.  Twelve further patients did 
not receive any allocated warfarin treatment (eight on warfarin 1mg and four on 
DAW), mostly due to patient choice.  All were included in the analysis.  
 
Warfarin Compliance 
Of the 1139 patients who started warfarin, 26 (2.3%) patients and/or their clinicians 
did not conform to warfarin dose. Of these, for the five patients allocated FDW, the 
clinician chose to prescribe the variable dose; twenty out of 21 patients on DAW took 
1mg warfarin daily either in error or by choice.  
The protocol stated that warfarin should be taken until catheter removal or 
thrombosis; only 155 (10%) of patients started warfarin 3 days prior to catheter 
insertion and of the 1139 patients starting warfarin, 106 (9%) stopped ‘early’ (more 
than 7 days before the catheter was removed), largely due to their chemotherapy 
being completed and the CVC was still in situ but also because of patient choice or 
thrombocytopenia; this was balanced across treatment arms.  Data on warfarin 
compliance were incomplete on 8% of patients. 
The CONSORT diagram, available on-line, shows detailed compliance data. 
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Thrombotic events 
Of the 1590 patients randomised, 85 (5.3%) had a radiologically confirmed CRT 
event. There were also 9 clinically suspected thromboses, not confirmed 
radiologically and classified as CVC complications.  Warfarin (of which 79% was 
FDW) did not reduce the incidence of CRT relative to control (24 (5.9%) vs 24 
(5.9%); RR=0.99, 95%CI 0.57–1.72, p=0.98) (Table 2a).  In contrast, there were 
significantly fewer CRT in those patients allocated DAW compared to FDW (13 
(2.8%) vs 34 (7.2%); RR=0.38; 95%CI 0.20–0.71, p=0.002).  Analysis of this primary 
outcome as time-to-event data showed comparable results (Figure 2). A further 36 
(2.3%) patients had a non-CRT event.  Neither warfarin (compared to control) nor 
DAW (compared to FDW) have any significant impact (p=0.30 and p=0.15 
respectively) on all thrombotic events (Table 2a).   Comparisons of the FDW and 
DAW groups separately with control are shown in Table 3 – there are no significant 
differences.  
 
The location of the 85 CRT were reported as follows:  32 upper limb, 17 axillary vein, 
16 subclavian vein, 10 internal jugular, 4 superior vena cava, 2 pulmonary emboli, 2 
catheter and 2 with site not stated.  The location of the 36 non-CRT events 
presented as 18 lower limb, 9 pulmonary emboli, 4 upper limb, 2 inferior vena cava, 
1 subclavian vein, 1 pulmonary vein and 1 portal vein. Non-CRT events were all 
venous with the exception of one upper limb arterial thrombosis. 
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Time to Thrombosis, Catheter – Patency and Infections 
For the 85 patients with a CRT, median time to CRT was 32 days from 
randomisation (IQR=13 to 76 days). Median time to CRT did not significantly differ in 
the warfarin vs control (25 vs 32 days, p=0.71), or DAW vs FDW (60 vs 31 days, 
p=0.51) comparisons.  Median time to all 121 thromboses (CRT and non-CRT) was 
44 days (IQR=13-84 days). CVCs were patent for a median time of 13.9 weeks for 
all patients.   There was no significant difference in the median duration of catheter 
patency across treatments.   124 patients (7.8%) were categorised as having one or 
more catheter-related infections;  there were no significant differences between 
treatments.   
 
Major bleeding and INR 
There was some evidence of an excess of major bleeding events in patients on 
warfarin vs control (RR=6.93, 95%CI 0.86-56.08, p=0.07) and in patients on DAW vs 
FDW (RR=2.28, 95%CI 0.95-5.48, p=0.09), although both failed to reach statistical 
significance.  An increase in moderately and severely raised INR without major 
bleeding was also demonstrated (Table 2b).  According to participating clinicians, 
warfarin may have contributed to the deaths of two patients receiving DAW; no 
thrombosis was reported as contributing to death.  
Given the fine balance between the clinical consequences of thrombosis and major 
bleeding, we examined a combined endpoint of thrombotic events plus major bleeds.  
This analysis revealed no significant difference between treatment arms for both 
comparisons (Table 2c).  
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Detailed INR readings were analysed from one centre with 54 patients on FDW and 
56 patients on DAW.  INR determinations were taken on average, 6 times for FDW 
and 19 times for DAW groups over a median timespan of 1.8 months and 5.1 
months respectively.  Median INR for FDW group was 1.10, (IQR 1.04-1.24); for 
DAW group was 1.69, (IQR 1.43-1.93).   
 
Overall Survival 
At the time of analysis, 532 patients were still alive with a median follow-up of 45 
months (range 26 to 88 months).   Of the 1058 reported deaths, 921 (87%) were due 
to cancer; 53 (5%), other causes; and 84 (8%), cause unknown.     No overall 
survival advantage was found from taking warfarin compared to control (HR=0.98, 
95%CI: 0.77-1.25, p=0.26) or found between the two dosing schedules (HR=0.91, 
95% CI 0.73-1.14, p=0.53) (Figure 3). 
 
Discussion 
This trial demonstrates that warfarin (79% FDW, 21% DAW) does not have a useful 
role in the prophylaxis of CRT.  The overall incidence of symptomatic CRT was 
relatively low (5.3%), in keeping with a general temporal trend12 brought about by 
improved catheter design and care13,14.  It is interesting to note that more clinicians 
than expected from the pre-trial survey were ‘certain’ of the indication for warfarin; 
they may have been influenced by the results of early studies and some were also 
high recruiters.  When compared to control, warfarinisation does not offer any 
advantage in reducing CRT.  Similarly, warfarin did not reduce the incidence of all 
thrombotic events or have any impact on survival. When FDW and DAW 
  Page 14 of 29 
respectively were compared directly with the control arm, there was no advantage 
demonstrated from either warfarin dose; however, the numbers in each arm are 
small (Table 3).  Conversely, when compared to FDW, DAW did significantly reduce 
the number of symptomatic CRT but at an increased cost in terms of major bleeds 
and additional INR monitoring.  This reduction in CRT events with DAW over FDW 
does not translate into a decrease in all thrombotic events and, in effect, is cancelled 
out when the combined endpoint of thrombosis plus major bleeding is observed.   
However, for clinicians still wishing to offer prophylactic oral anticoagulation to 
patients with CVCs, for example, those at high thrombotic risk15,16,17 and who are 
prepared to accept the related toxicity profile, dose adjusted warfarin may be the 
more logical choice.   Exploratory subgroup analysis will be the topic of a future 
paper. 
Our findings are in keeping with the results of more recent studies on 
thromboprophylaxis in cancer patients with CVC.   Bern et al (1990) compared 1 mg 
warfarin for 90 days to control in cancer patients with long term central venous 
catheters4.  VTE were detected symptomatically and by routine venogram in 15 of 
40 (37.5%) control patients in comparison to 4 of the 42 (9.5%) patients on warfarin 
(p<0.001).  Monreal et al3 (1996) randomised a similar group of patients to the low 
molecular weight heparin (LMWH), dalteparin (2500iu subcutaneously, daily for 90 
days) or control.  Early trial closure was precipitated by differential upper limb 
thrombosis rates (1/16 dalteparin arm vs 8/13 in control patients, p=0.002), 
confirmed by routine venography.  A Korean group, in 1999, randomised 80 cancer 
patients with CVCs to 1mg warfarin vs control and reported thrombosis rates of 13% 
vs 29% respectively (p=0.07)18.   Although small, these three trials suggested a 
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benefit in using prophylactic anticoagulation by reducing thrombosis rates with 
minimal toxicity.   However, more recent trials have found no benefit from warfarin 
intervention.  Heaton et al (2002) examined the effects of 1mg fixed daily dose of 
warfarin versus control on thromboprophylaxis in 88 haemato-oncology patients 
receiving chemotherapy via CVCs5.  No significant difference in symptomatic 
thromboses (18% vs 12% respectively, p=0.4) was demonstrated.  Similarly, Couban 
and colleagues recorded the number of symptomatic thrombotic events in a trial of 
255 patients (80% with haematological malignancies) receiving warfarin 1mg or 
placebo for 9 weeks6.  Overall CRT rates were low; 4.6% with warfarin and 4.0% 
with placebo (HR, 1.2, 95% CI, 0.37 – 3.94).  It appears more difficult to keep cancer 
patients on warfarin within target INR range20,21.  Our INR analysis showed a similar 
variability to other studies20,21. INR monitoring of patients receiving DAW was 
problematic in some centres 
LMWHs recently evaluated in trials, have also proven no more effective than control 
in the prophylaxis of CRT.  Verso et al adopted a primary endpoint of thrombosis 
(measured at routine investigation) in a trial of enoxaparin (40mg once daily for 6 
weeks) vs placebo7.  In 385 cancer patients, thrombosis rates were found to be 
similar in both arms (14% enoxaparin vs 18% placebo, p=0.35).   Karthaus and 
colleagues showed no symptomatic thromboprophylactic effect of dalteparin 
(5000iu/day) in comparison to placebo (3.7% and 3.4% respectively, p=0.88)8.  Our 
results concur both with a recent pooled estimate of the Bern and Heaton trials19, 
confirming a lack of benefit from warfarin.  When WARP data were added to a 
previous meta-analysis of warfarin intervention vs control in the prophylaxis of 
thrombosis in cancer patients with CVCs12, the earlier advantage seen for warfarin 
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(OR 0.58, CI 0.34-1.01; p=0.05) was reduced (OR 0.75, CI 0.5-1.1; p=0.1) (Figure 
4).   
Taking these trials in concert with this definitive report, it is noticeable that the 
incidence of symptomatic CRT reported in clinical trials has markedly declined over 
the past decade12.  The improvements in catheter technology, placement and 
aftercare are contributing to this reduction13,14.  The clinically relevant benefit/risk 
outcome of (prophylaxis of) thrombotic events plus major bleeding demonstrated no 
advantage in using any dose of warfarin.  These findings only add to the assertion, ‘it 
is time to move on from warfarin’ for thromboprophylaxis in the cancer patient 
population.   
 
MANUSCRIPT:  2995 WORDS
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Table 1: Baseline Patient Characteristics 
Comparison Control Dose evaluation 
Factor Grouping No Warfarin 
N (%) 
N=404 
U3* : N=161 
U2*: N=243 
Warfarin 
N (%) 
N=408 
U3* : N=166 
U2*: N=242 
FDW  
N (%) 
N=471  
U3*: N=82 
C2*: N=389 
DAW  
N (%) 
N=473 
U3*: N=84 
C2*: N=389 
Gender Male 247 (61%) 252 (62%) 253 (54%) 265 (56%) 
Age (yrs) Median (IQR)  61 (53-68) 60 (53-68) 59 (51-66) 60 (53-67) 
WHO Performance 
Status 
0 221 (55%) 225 (55%) 263 (56%) 272 (58%) 
 1 168 (42%) 151 (37%) 178 (38%) 161 (34%) 
 2/3 10 (2%) 21 (5%) 23 (5%) 29 (6%) 
 Not known 5 (1%) 11 (3%) 7 (1%) 11 (2%) 
Stage of disease No residual/early 130 (32%) 134 (33%) 171 (36%) 138 (29%) 
 Advanced 273 (68%) 269 (66%) 294 (62%) 330 (70%) 
 Not known 1 (0.3%) 5 (1%) 6 (1%) 5 (1%) 
Disease site Colorectal 201 (50%) 217 (53%) 226 (48%) 243 (51%) 
 Upper GI 109 (27%) 92 (23%) 95 (20%) 98 (21%) 
 Breast 32 (8%) 32 (8%) 82 (17%) 67 (14%) 
 Other 50 (12%) 54 (13%) 52 (11%) 49 (10%) 
 Not known 12 (3%) 13 (3%) 16 (3%) 16 (3%) 
Catheter Placement Central 146 (36%) 150 (37%) 226 (48%) 228 (48%) 
 Peripheral 258 (64%) 258 (63%) 245 (52%) 245 (52%) 
Sclerosant potential Non-sclerosant 172 (43%) 169 (41%) 235 (50%) 236 (50%) 
 Sclerosant 232 (57%) 239 (59%) 236 (50%) 237 (50%) 
Treatment length <24 hours 64 (16%) 68 (17%) 87 (18%) 86 (18%) 
 24 hours 340 (84%) 340 (83%) 384 (82%) 387 (82%) 
 *U = Uncertain Indication for Warfarin; C= Certain Indication for Warfarin; 3= 3arm; 2= 2 arm 
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Table 2a: Thrombotic Events* 
 Warfarin Evaluation Dose Evaluation  
 
No Warfarin 
 
N=404 
Warfarin 
 
N= 408 
Relative Risk 
(95% CI) 
p-value 
FDW 
 
N= 471 
DAW 
 
N= 473 
Relative Risk 
(95% CI) 
p-value 
CRT Events 24 (5.9%) 
 
24 (5.9%) 
 
0.99 
(0.57, 1.72) 
p=0.98 
34 (7.2%) 
 
13 (2.8%) 
 
0.38 
(0.20, 0.71) 
p=0.002 
No event 370 (91.6%) 
 
372 (91.2%)  433 
(91.9%) 
448 
(94.7%) 
 
Not known 10 (2.5%) 12 (2.9%)  4 (0.9%) 12 (2.5%)  
All thrombotic events 
(CRT& non-CRT) 
 
38 (9.4%) 
 
30 (7.4%) 
 
0.78  
(0.50, 1.24) 
p=0.30 
37 (7.9%) 
 
26 (5.5%) 
 
0.70 
(0.43,1.14) 
p=0.15 
No event 356 (88.1%) 368 (90.2%)  430 
(91.3%) 
438 
(92.6%) 
 
Not known 10 (2.5%) 12 (2.9%)  4 (0.9%) 12 (2.5%)  
 
Table 2b: Bleeding and raised INR (moderate and severe) 
Major Bleeding & no 
reported raised INR 
1 3  5 7  
Major Bleeding &  
raised INR 
0 4  2 9  
Total Major Bleeding 1 (0.3%) 7 (1.7%) 
6.93 
(0.86,56.08) 
p=0.07 
7 (1.5%) 16 (3.4%) 
2.28 
(0.95,5.48) 
p=0.09 
Moderate and severe 
raised INR & no major 
bleeding 
0 3  1 12  
 
Table 2c: Combined Thrombosis Major and Bleeding  
CRT Events 24 24  34 13  
Total Major Bleeding 1 7  7 16  
Total 25 (6.2%) 31 (7.6%) 
1.23 
(0.83,1.52) 
0.51 
41(8.7%) 29(6.1%) 
0.84 
(0.74,2.04) 
p=0.17 
All thrombotic events 
(CRT& non-CRT) 
38 30  37 26  
Total Major Bleeding 1 7  7 16  
Total 39 (9.7%) 37 (9.1%) 
0.94 
(0.61,1.44) 
0.87 
44 (9.3%) 42 (8.9%) 
0.95 
(0.64,1.42) 
p=0.89 
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Table 3: Thrombotic Events – Other Randomised Comparisons 
 Control vs FDW Control vs DAW*  
 
No Warfarin 
 
N=404 
FDW 
 
N= 324 
Relative Risk 
(95% CI) 
p-value 
No Warfarin 
 
N= 161 
DAW 
 
N= 84 
Relative Risk 
(95% CI) 
p-value 
CRT Events 24 (5.9%) 
 
22 (6.8%) 
 
1.10 
(0.64, 1.89) 
p=0.72 
5 (3.1%) 
 
2 (2.4%) 
 
0.77 
(0.15, 3.87) 
p>0.99 
All thrombotic 
events (CRT& 
non-CRT) 
 
38 (9.4%) 
 
28 (8.6%) 
 
0.91  
(0.57, 1.45) 
p=0.69 
13 (8.1%) 
 
2 (2.4%) 
 
0.29 
(0.07,1.28) 
p=0.10 
Major Bleeding 1 (0.3%) 3 (0.9%) 3.74 
(0.39, 35.79) 
p=0.33 
0 (0%) 4 (4.8%) Not 
calculable 
p=0.01 
Total major 
bleeding and 
CRT events 
25 (6.2%) 25 (7.7%) 1.25 
(0.73, 2.13) 
p=0.51 
5 (3.1%) 6 (7.1%) 2.30 
(0.72, 7.32) 
p=0.19 
Total major 
bleeding and all 
thrombotic 
events 
39 (9.7%) 31 (9.6%) 0.99 
(0.63, 1.55) 
p>0.99 
13 (8.1%) 6 (7.1%) 0.88 
(0.35, 2.24) 
p=0.99 
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Figure 1 – Trial Flow Diagram 
 
 
 
Figure 1 - Trial Structure at Randomisation 
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* once daily:     CRT – Catheter-related thromboses 
Uncertain 
n=812 
1mg warfarin od* 
n=389 
CRT - 26 
DAW warfarin od* 
n=389 
CRT - 11 
No warfarin 
n=161 
CRT - 5 
Are you (clinician) willing to participate in the dose adjusted warfarin (DAW) arm?  
Certain 
n=778 
 
1mg warfarin od* 
n=82 
CRT - 8  
 
DAW warfarin od* 
n=84 
CRT - 2 
No warfarin 
n=243 
CRT - 19 
1mg warfarin od* 
n=242 
CRT - 14 
YES – 3 arm study 
n=327 
Are you (clinician) certain or uncertain of the benefits of warfarin in the prophylaxis of thrombosis in cancer patients with CVCs? 
NO – 2 arm study 
n=485 
vs Warfarin 
n=408 
(242+82+84) 
FDW; n=324 
DAW; n=84 
CRT - 24 
 
and vs 1mg warfarin 
n=471 
(82+389) 
CRT - 34 
DAW warfarin  
n=473 
(84+389) 
CRT - 13 
2 parallel randomised studies: No warfarin 
n=404 
(161+243) 
CRT - 24 
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Figure 2 – Time to Thrombosis 
2a) Time to Thrombosis – Control vs Warfarin 
 
 
 
 
 
 
 
 
 
2b) Time to Thrombosis – FDW vs DAW  
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Figure 3: Overall survival 
 3a) Overall Survival - Control vs Warfarin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3b) Overall Survival - FDW vs DAW 
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Figure 4 
Meta-analysis of prevention of thrombosis with warfarin vs control in cancer patients 
with CVCs 
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